Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, ARS Pharmaceuticals Inc (NASDAQ: SPRY) closed at $16.79 up 0.42% from its previous closing price of $16.72. In other words, the price has increased by $0.42 from its previous closing price. On the day, 0.88 million shares were traded. SPRY stock price reached its highest trading level at $17.08 during the session, while it also had its lowest trading level at $16.54.
Ratios:
For a deeper understanding of ARS Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 32.78 and its Current Ratio is at 32.78. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On August 13, 2024, Raymond James Upgraded its rating to Strong Buy which previously was Outperform and also upped its target price recommendation from $18 to $22.
Leerink Partners reiterated its Outperform rating for the stock on August 12, 2024, while the target price for the stock was revised from $19 to $20.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 16 ’24 when Scott Kathleen D. sold 12,500 shares for $16.00 per share. The transaction valued at 200,000 led to the insider holds 4,949 shares of the business.
Tanimoto Sarina sold 100,000 shares of SPRY for $1,487,595 on Oct 15 ’24. The CHIEF MEDICAL OFFICER now owns 1,298,499 shares after completing the transaction at $14.88 per share. On Oct 15 ’24, another insider, Lowenthal Richard E, who serves as the PRESIDENT AND CEO of the company, sold 100,000 shares for $14.88 each. As a result, the insider received 1,487,595 and left with 1,298,499 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRY now has a Market Capitalization of 1627649536 and an Enterprise Value of 1402279680. For the stock, the TTM Price-to-Sale (P/S) ratio is 3255.25 while its Price-to-Book (P/B) ratio in mrq is 7.56. Its current Enterprise Value per Revenue stands at 2804.559 whereas that against EBITDA is -24.743.
Stock Price History:
Over the past 52 weeks, SPRY has reached a high of $16.89, while it has fallen to a 52-week low of $3.38. The 50-Day Moving Average of the stock is 21.64%, while the 200-Day Moving Average is calculated to be 68.59%.
Shares Statistics:
For the past three months, SPRY has traded an average of 1.12M shares per day and 885950 over the past ten days. A total of 96.41M shares are outstanding, with a floating share count of 49.21M. Insiders hold about 49.24% of the company’s shares, while institutions hold 39.06% stake in the company. Shares short for SPRY as of 1727654400 were 11097485 with a Short Ratio of 9.94, compared to 1724976000 on 10960219. Therefore, it implies a Short% of Shares Outstanding of 11097485 and a Short% of Float of 21.57.
